Illumina's (ILMN) Overweight Rating Reiterated at Stephens

Illumina (NASDAQ:ILMN - Get Free Report)'s stock had its "overweight" rating reissued by Stephens in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $170.00 price objective on the life sciences company's stock. Stephens' price target would indicate a potential upside of 50.68% from the stock's current price.

Other analysts have also recently issued research reports about the company. HSBC cut Illumina from a "buy" rating to a "hold" rating in a report on Tuesday, January 16th. OTR Global reiterated a "mixed" rating on shares of Illumina in a report on Wednesday, March 20th. Robert W. Baird boosted their target price on Illumina from $125.00 to $128.00 and gave the stock a "neutral" rating in a report on Friday. Barclays boosted their target price on Illumina from $85.00 to $100.00 and gave the stock an "underweight" rating in a report on Wednesday, April 10th. Finally, Scotiabank decreased their target price on Illumina from $185.00 to $176.00 and set a "sector outperform" rating for the company in a report on Monday. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $164.65.

Illumina Trading Down 5.2 %

Shares of NASDAQ ILMN traded down $6.16 on Tuesday, reaching $112.82. 2,949,514 shares of the company traded hands, compared to its average volume of 1,727,441. Illumina has a fifty-two week low of $89.00 and a fifty-two week high of $213.91. The company has a 50 day moving average of $129.13 and a 200 day moving average of $126.95. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $17.97 billion, a PE ratio of -13.84 and a beta of 1.20.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.05. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the prior year, the company posted $0.08 EPS. The company's quarterly revenue was down 1.0% compared to the same quarter last year. On average, equities research analysts forecast that Illumina will post 0.91 earnings per share for the current fiscal year.

Insider Activity

In other Illumina news, CEO Jacob Thaysen bought 7,330 shares of Illumina stock in a transaction dated Thursday, February 22nd. The stock was bought at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the purchase, the chief executive officer now owns 14,861 shares in the company, valued at approximately $2,010,544.69. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.17% of the company's stock.

Institutional Investors Weigh In On Illumina

Several institutional investors and hedge funds have recently made changes to their positions in ILMN. Cambridge Investment Research Advisors Inc. raised its position in shares of Illumina by 43.9% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 7,398 shares of the life sciences company's stock valued at $1,016,000 after acquiring an additional 2,258 shares in the last quarter. Stratos Wealth Partners LTD. raised its position in shares of Illumina by 8.4% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 5,275 shares of the life sciences company's stock valued at $724,000 after acquiring an additional 410 shares in the last quarter. Independent Advisor Alliance increased its position in Illumina by 8.6% in the third quarter. Independent Advisor Alliance now owns 1,595 shares of the life sciences company's stock worth $219,000 after buying an additional 126 shares during the period. Brown Advisory Inc. increased its position in Illumina by 4.4% in the third quarter. Brown Advisory Inc. now owns 4,140 shares of the life sciences company's stock worth $568,000 after buying an additional 176 shares during the period. Finally, Verdence Capital Advisors LLC increased its position in Illumina by 9.3% in the third quarter. Verdence Capital Advisors LLC now owns 2,945 shares of the life sciences company's stock worth $404,000 after buying an additional 250 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.